Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia

maanantai 16. marraskuuta 2026 päivittänyt: Jiangsu Guiqiong Pharmaceutical Co., Ltd.

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia

This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia. This study comprises a double-blind treatment phase, followed by an open-label treatment phase for eligible participants upon completion of the double-blind phase.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study designed to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.

Eligible participants are randomly assigned at a 1:1:1 ratio to one of three treatment arms: Arm A (4 mg SXRN injection), Arm B (6 mg SXRN injection), or Arm C (placebo). During the double-blind treatment phase, study drug or placebo is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days). Investigators and participants remain blinded to treatment assignment during this phase.

Upon completion of the double-blind phase, participants assessed by the investigator as having no clinical progression or intolerable toxicity will enter the open-label treatment phase and receive a uniform dose of 4 mg SXRN injection. The dosing regimen in the open-label phase is identical to that in the double-blind phase: 5 consecutive days of dosing followed by a 2-day break, with each cycle of 21 days. Participants will continue study treatment until any of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, death, or other pre-defined treatment discontinuation criteria, whichever comes first.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

96

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Beijing, Kiina
        • National Cancer Center/Cancer Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 75 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

The participant must meet all the criteria below:

  • 1. Male or female, aged 18~75 at the time of signing the ICF;

  • 2. Histologically or cytologically confirmed advanced malignancy of one of the following: pancreatic cancer; non-small cell lung cancer (NSCLC); colorectal cancer;

  • 3. Disease status and prior treatment history (meet any one of the following):

    1. Pancreatic cancer: Locally advanced (unresectable) or metastatic pancreatic ductal adenocarcinoma, with treatment failure after at least 2 lines of prior systemic anti-tumor therapy (may include gemcitabine, nab-paclitaxel, irinotecan, platinum agents, and fluoropyrimidines);
    2. Non-small cell lung cancer (NSCLC): Stage IIIB/IV NSCLC, with treatment failure after at least 2 lines of prior systemic anti-tumor therapy (must include platinum-based chemotherapy; patients with positive driver gene must have received corresponding targeted therapy);
    3. Colorectal cancer: Metastatic colorectal cancer, with treatment failure after at least 3 lines of prior systemic anti-tumor therapy (must include fluoropyrimidines, oxaliplatin, and irinotecan); patients with MSI-H/dMMR tumors must have received anti-PD-1/PD-L1 therapy followed by treatment failure.
  • 4. Diagnosis of cancer anorexia-cachexia based on the cachexia staging criteria from the 2025 Chinese Guidelines for the Diagnosis and Treatment of Cancer Anorexia-Cachexia Syndrome with consideration of Chinese population characteristics, i.e., meeting the following criteria (either ①② or ①③):

    1. Involuntary weight loss >5% in 6 months; OR weight loss >2% when BMI <18.5 kg/m²; OR weight loss >2% accompanied by muscle mass depletion;
    2. Anorexia (VAS score ≤70, or FAACT-A/CS-12 score ≤37);
    3. CRP>5 mg/L;
  • 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;

  • 6. Expected survival time ≥12 weeks;

  • 7. Lab results and organ function tested within 7 days before the initial infusion meet the following criteria:

Complete Blood Count: Absolute Neutrophil Count (ANC) ≥ 1.0×109/L; Platlets (PLT) Count ≥ 75×109/L; Hemoglobins (Hb) ≥ 80 g/L.

Note: Participants with chronic anemia caused by underlying tumor or cachexia may be enrolled if the investigator assesses the condition as stable; anemia resulting from active bleeding is excluded.

Blood Biochemistry: Total bilirubin (TBIL) ≤3.0 × upper limit of normal (ULN); Serum creatinine (SCr) ≤1.5 × ULN or creatinine clearance (CrCl) by Cockroft-Gault formula ≥30 mL/min; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN; for participants with concurrent liver metastases, AST and ALT ≤5.0×ULN and ALP ≤6.0×ULN;

Blood coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN.

Note: for participants receiving precautious anti-coagulation treatment, the investigator shall determine whether INR and APTT remains in a safe and effective range for treatment.

Echocardiogram: Left Ventricular Ejection Fraction (LVEF) ≥50%;

  • 8. Participants are capable of understanding and voluntarily signing the written informed consent form (ICF); participants must be willing and able to complete study procedures and follow-up assessments.

Exclusion Criteria:

Participants who meet any of the criteria below must be excluded:

  • 1. Reversible causes of reduced dietary intake as determined by the investigator, which may include but are not limited to mechanical obstruction resulting in patients' inability to eat;

  • 2. Patients who have received any appetite-enhancing or weight-loss-improving medications (including marketed prescription drugs and investigational agents under clinical trial) within 28 days before the first study drug administration or 5 half-lives of the drug (whichever is shorter), including but not limited to anamorelin, progestogens such as medroxyprogesterone acetate, cannabinoids, and medical cannabis;

  • 3. Patients who are only able to receive tube feeding and parenteral nutrition and cannot take food orally;

  • 4. Patients with cachexia clearly attributable to other underlying conditions, such as severe chronic obstructive pulmonary disease (COPD), AIDS, etc.;

  • 5. Hormonal therapies judged by the investigator to have effects for improving tumor anorexia-cachexia;

  • 6. Patients who have undergone major surgery or interventional procedures within 4 weeks prior to the first dose, or who are scheduled to receive such procedures during the trial (excluding tumor biopsy, puncture, etc.);

  • 7. Patients with toxicities from previous antitumor therapies that have not yet recovered to ≤ Grade 2 or baseline levels (except for toxicities judged by the investigator as to pose no safety risk, such as alopecia, or asymptomatic hypothyroidism induced by immune checkpoint inhibitors that is stable and only requires thyroid hormone replacement therapy);

  • 8. Clinically uncontrolled serous cavity effusion (pleural effusion, ascites, pericardial effusion): moderate or greater effusion; local therapy (including drainage, peritoneal shunt, cell-free concentrated ascites reinfusion therapy, etc.) within 2 weeks before screening or planned within 2 weeks; significant effusion increase within 2 weeks after local therapy; requirement for long-term indwelling catheter. Participants meeting any condition or deemed by the investigator unsuitable for enrollment will be excluded;

  • 9. Patients with central nervous system metastases requiring intervention;

  • 10. History of other malignancies, except for those who have undergone curative treatment with no recurrence within 5 years, such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, etc.;

  • 11. History of immunodeficiency, including acquired or congenital immunodeficiency diseases, organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;

  • 12. (Non-infectious) pulmonary inflammation/interstitial lung disease requiring steroid therapy within 4 weeks prior to the first infusion;

  • 13. Participants with a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:

    1. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, etc.;
    2. Participants with New York Heart Association (NYHA) Class III-IV cardiac dysfunction;
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade ≥3 cardiovascular and cerebrovascular events occurring within 6 months prior to the first study drug administration;
  • 14. Hypertension uncontrolled by a stable regimen of antihypertensive medication (systolic blood pressure ≥160 mmHg, and/or diastolic blood pressure ≥100 mmHg);

  • 15. Participants with active chronic hepatitis B (e.g., HBsAg positive or HBcAb positive with HBV DNA above the lower limit of detection), active hepatitis C (e.g., HCV antibody positive with HCV RNA above the lower limit of detection), or human immunodeficiency virus (HIV) infection;

  • 16. Active infection requiring systemic therapy within 2 weeks prior to the first dose;

  • 17. History of active tuberculosis infection within 1 year prior to the first dose;

  • 18. Any other uncontrolled or significant comorbid disease(s), either currently or historically, that by the investigator's judgment may interfere with trial participation or evaluation;

  • 19. Known allergies or contraindications to the study drug (SXRN injection) or process-related impurities of its drug substance (e.g., spectinomycin);

  • 20. For premenopausal female participants (postmenopausal females must be amenorrheic for at least 12 months to be considered of non-childbearing potential): participants with positive serum pregnancy test, or participants of childbearing potential (including female partners of male participants) who, in the investigator's opinion, are likely to become pregnant, are breastfeeding, or are unwilling to use effective contraception during the study and for at least 6 months after the last dose of the study drug;

  • 21. Any other condition that considered by the investigator as to render the patient unsuitable for participation in the study.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: 4 mg SXRN

4 mg SXRN injection is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days).

4 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

6 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

Kokeellinen: 6 mg SXRN

6 mg SXRN injection is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days).

4 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

6 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

Placebo Comparator: Placebo

Placebo is administered via intravenous infusion once daily for 5 consecutive days followed by a 2-day break, for a total of 3 weeks (21 days).

Matching placebo, administered by intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in anorexia from baseline at Week 3
Aikaikkuna: Baseline to Week 3

Change in anorexia from baseline assessed at Week 3 using the Functional Assessment of Anorexia/Cachexia Therapy-Anorexia/Cachexia Subscale-12 (FAACT-A/CS-12). The scale ranges from 0 to 48. Higher scores indicate better outcome.

Baseline to Week 3
Change in comprehensive physical function from baseline at Week 3
Aikaikkuna: Baseline to Week 3

Change in physical function from baseline assessed at Week 3 using 6-minute walk test (6MWT).

Baseline to Week 3

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in quality of life from baseline at Week 3
Aikaikkuna: Baseline to Week 3

Change in quality of life from baseline assessed at Week 3 using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The score ranges from 0 to 100. Higher scores indicate better outcome.

Baseline to Week 3
Change in dietary intake from baseline at Week 3
Aikaikkuna: Baseline to Week 3

Change in dietary intake from baseline assessed at Week 3 using the Simplified Dietary Self-Assessment Questionnaire. The scale ranges from 1 to 5. Higher scores indicate better outcome.

Baseline to Week 3
Change in body weight/lean body mass (LBM) from baseline at Week 3
Aikaikkuna: Baseline to Week 3
Baseline to Week 3
Change in pain from baseline at Week 3
Aikaikkuna: Baseline to Week 3

Change in pain from baseline assessed at Week 3 using the analgesic medication records and the pain domain score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The pain domain score ranges from 0 to 100. Higher scores indicate worse outcome.

Baseline to Week 3
Change in ECOG performance status from baseline at Week 3
Aikaikkuna: Baseline to Week 3

Change in performance status from baseline assessed at Week 3 using the Eastern Cooperative Oncology Group (ECOG) Performance Status. Possible grades range from 0 to 5. Lower grades indicate better outcome.

Baseline to Week 3

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Tiistai 1. joulukuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 1. elokuuta 2027

Opintojen valmistuminen (Arvioitu)

Keskiviikko 1. joulukuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 16. lokakuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 16. lokakuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 22. lokakuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 19. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 16. marraskuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muut tutkimustunnusnumerot

  • AA0103

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .